Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2026

The definitive benchmark for cancer monoclonal antibody dealmaking

Cancer monoclonal antibody partnering is driven by targeted biologic therapies, with deal structures reflecting the continued evolution of antibody-based approaches across oncology indications.

This report provides a comprehensive and structured analysis of 650+ cancer monoclonal antibody collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how monoclonal antibody deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by development stage, antibody type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly competitive and innovation-driven oncology landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within monoclonal antibody partnerships, particularly in areas involving differentiated biologics and targeted treatment strategies.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark oncology biologics transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing and co-development opportunities
• Support internal strategy with robust, defensible data
• What's included
• 650+ cancer monoclonal antibody collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and antibody type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cancer monoclonal antibody dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how monoclonal antibody partnerships are structured, negotiated, and valued.